Epic Bio Announces the Appointment of Weston Miller, M.D., as Chief Medical Officer
October 17, 2023 06:00 ET
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
Epic Bio to Present at the Upcoming BMO Life Sciences Private Company Showcase
October 05, 2023 09:00 ET
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
Epic Bio to Present Preclinical Data at 28th International Annual Congress of the World Muscle Society
September 28, 2023 09:00 ET
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
Epic Bio to Present at Upcoming BMO Biopharma Spotlight Series Event
September 19, 2023 09:00 ET
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
Epic Bio Reports Discovery of Exceptionally Durable Gene Activators and Creation of Machine Learning Algorithm to Design New Activators
September 14, 2023 12:00 ET
|
Epic Bio
- Vast high-throughput screening study used to train unique machine learning algorithm to design synthetic activators - - Rational engineering produced activators that induce the most...
Epic Bio Presents Compelling Preclinical Data Supporting Clinical Initiation of EPI-321 for FSHD
June 16, 2023 06:16 ET
|
Epic Bio
- NHP studies demonstrate EPI-321’s favorable safety and pharmacokinetic profile - - IND and CTA applications planned for 2023 - SOUTH SAN FRANCISCO, Calif., June 16, 2023 (GLOBE NEWSWIRE) --...
Epic Bio to Participate in a Fireside Chat at the Stifel Genetic Medicines Day 2023
May 23, 2023 08:00 ET
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., May 23, 2023 (GLOBE NEWSWIRE) -- EPIC BIO, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
Epic Bio Presents Preclinical Data on EPI-321 for Facioscapulohumeral Muscular Dystrophy at ASGCT 26th Annual Meeting
May 19, 2023 06:00 ET
|
Epic Bio
- Oral presentation highlights EPI-321 effects on multiple clinically relevant markers - - IND application for EPI-321 planned for 2023 - SOUTH SAN FRANCISCO, Calif., May 19, 2023 (GLOBE...
Epic Bio to Present Preclinical Data at American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
May 04, 2023 09:00 ET
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Epic BIO, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
SOLVE FSHD Invests in Epic Bio to Advance Potentially Curative Therapy
April 18, 2023 09:00 ET
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...